Premium
Emphysematous Cholecystitis in a Patient with Gastrointestinal Stromal Tumor Treated with Sunitinib
Author(s) -
Lopes Gilberto Lima,
Lima Caio Max Rocha
Publication year - 2007
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.27.5.775
Subject(s) - medicine , sunitinib , nausea , stromal tumor , vomiting , gist , adverse effect , leukocytosis , gastroenterology , surgery , stromal cell , cancer
A 50‐year‐old man had a metastatic gastrointestinal stromal tumor that was refractory to imatinib. He was prescribed a 6‐week course of treatment with oral sunitinib 50 mg/day. During the fourth week of his first cycle of treatment with the drug, the patient developed acute‐onset, right upper quadrant pain associated with nausea, vomiting, and fever; laboratory tests revealed leukocytosis and mild hyperbilirubinemia. He was diagnosed with acute emphysematous cholecystitis, which was treated with broad‐spectrum antibiotics and percutaneous cholecystostomy. His symptoms resolved, and he successfully completed his course of therapy with sunitinib. Using the Naranjo adverse drug reaction probability scale, a score of 5 was derived, which indicates that the likelihood was probable that this adverse event was caused by sunitinib.